FREE ADVICE FROM AN EXPERIENCED CONSULTANT
TESTS GENERALLY HAVE SHELF LIVES OF 12+ MONTHS
NZQA Unit Standards / Workplace Drug Testing
D&A Treatment Centres
Drug Testing Consumables
Breath Alcohol Screening/BrAC
FOC Training : Overview to AS/NZ4308:2008
NZQA Unit Standards for Drug Testing
Urine Vs Saliva
Reading Test Results
FAQ's Drug Testing
Privacy & Legal Policies
Terms of Trade
Our Guarantee / Returns Policy
> Rapid Antigen Immunoassay Screen /Nasal to detect SARS-CoV-2
Rapid Antigen Immunoassay Screen /Nasal to detect SARS-CoV-2
Move mouse over the image to magnify
Refer a friend
Nasal swab to detect, defend & defeat Covid 19
First Sign SARS-CoV-2 Antigen Nasal Swab Screen
The First Sign SARS-CoV-2
is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens directly collected from individuals suspected of COVID 19 by their healthcare provider within five days of symptom onset
This test has been authorized for use at the POC (Point of Care) for those that meet the requirements to perform moderate, high or waived complexity tests i.e. in-patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation.
The First Sign SARS-CoV-2 Antigen test does not differentiate between SARS-CoV and SARS-CoV-2
Results are for the identification of the SARS-CoV-2 nucleocapsid protein antigen. The antigen is generally detectable in direct nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of the disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary for patient management.
This test is intended for use by medical professionals or trained operators who are proficient in performing clinical laboratory personnel or individuals specifically trained in Point of Care settings.
A new coronavirus (201 -nCov) was identified in December 2019, which has since resulted in millions of confirmed human infections worldwide. Cases of severe illness and hundreds of thousands of deaths worldwide have now been reported February 11, 2020 saw the International Committee of Taxonomy of Viruses (CTV) rename the virus SARS_CoV-2.
The median incubation time is estimated to be approximately 5 days with symptoms to be present within 12 days of infection.
The symptoms of COVID 19 are similar to other viral respiratory diseases and include fever, cough, shortness of breath.
The First Sign SARS-CoV-2 Antigen screen is a lateral flow immunoassay for the qualitative detection of SARS-CoV-2 directly from specimen swabs eluted in an extraction buffer solution.
The First Sign SARS-CoV-2 Antigen Test Kit contains all components required to conduct an assay for SARS-CoV-2.
To Read More
Principles of test/ Precautions
Device Design / Test Materials
Storage & Stability
Specimen Collection & Handling
Specimen Collection Procedure
Swab Extraction Procedure
Specimen Test Procedure
You might also be interested in ...
Innoscreen Rapid Tilt (QTY -100 units)
6 Panel Drug Screen 4 boxes ($12.38ea)
COTININE (COT) Single Panel (5 pack)
Urine / (COT) Min Qty 5 pack $42 ($8.40 each)
Enquire for price
Breath Alcohol Analyzer
Oral Cube 7+ Alcohol (Saliva)
Oral Fluids screen for the 6 drugs of abuse + K2 (synthetic cannabinoids) & Alcohol
ECO Cup II 6 Panel
Surestep EZI Cup
InnoScreen Split Cup
Alcohol (ALC)Single Panel
Barbituate Single Panel
Cotinine (COT)/Nicotine SP
Fentanyl (FEN) Single Panel
Marijuana (THC) Single Panel
MDMA (Ecstasy) Single Panel
Methadone (MTD) Single Panel
Oxycodone Single Panel
SARS-CoV-2 Antigen Test
Synthetic Cannabinoids (K2)
Meth & THC 2 panel
Oral Cube 7+ Saliva
Drugcheck 3000 Saliva
Drug Testing Consumables
D&A Treatment Clinics
Drager 5510 BrAC
lco Stop 2010 BrAC
Single Panel Urine Screen /ALCOHOL
NZQA Unit Standards
NZQA Refresher Training
Overview Training to AS/NZ 4308:2008
Training Videos / Correct Procedural Use
CONTACT US :